Men are not the only ones who suffer from sexual dysfunctions and women everywhere have been waiting for help for when they suffer from a poor libido. Sprout Pharmaceuticals may have the answer with its new drug called flibanserin.
The drug treats hypoactive sexual desire disorder, which causes a persistent biological lack of desire for sex that affects 1 in 10 women.
Flibanserin was twice rejected previously by the FDA because side effects like sleepiness, dizziness and nausea. But this week the FDA is thought to be ready to approve it on its third try.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
A movement called “Even the Score” has gotten over 40, 000 signatures for its on line petition. It says, “Women have waited long enough. In 2015, gender equality should be the standard when it comes to access to treatments for sexual dysfunction.”
Susan Scanlan, the organization’s chair, said in a statement that “Women deserve the safety and peace of mind that comes with access to FDA-approved medical treatments for HSDD, “”This week’s FDA advisory committee meeting represents a pivotal moment for women’s health.”
Cindy Whitehead, CEO of Sprout Pharmaceuticals, said, “Our greatest pride would be that we’ve answered an important need for patients.Women still don’t have a single medical treatment for this condition and if this could open a pipeline for other treatment options it would be a great achievement.”
